PMID- 38464337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240312
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 27
IP  - 4
DP  - 2024 Apr
TI  - Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to 
      predict the progression of lung squamous cell carcinoma.
PG  - 186
LID - 10.3892/ol.2024.14320 [doi]
LID - 186
AB  - Ferroptosis, an iron-dependent form of regulated cell death driven by excessive 
      lipid peroxidation, is implicated in the development and therapeutic responses of 
      cancer. However, the role of ferroptosis-related gene profiles in lung squamous 
      cell carcinoma (LSCC) remains largely unknown. The present study aimed to 
      identify the prognostic roles of ferroptosis-related genes in LSCC. Sequencing 
      data from the Cancer Genome Atlas were analyzed and ferroptosis-related gene 
      expression between tumor and para-tumor tissue was identified. The prognostic 
      role of these genes was also assessed using Kaplan-Meier analyses and univariate 
      and multivariate Cox proportional hazards regression model analyses. 
      Immunological correlation, tumor stemness, drug sensitivity and the 
      transcriptional differences of heat shock protein (HSP)A5 in LSCC were also 
      analyzed. Thereafter, the expression of HSPA5 in 100 patients with metastatic 
      LSCC was evaluated using immunohistochemistry (IHC) and the clinical significance 
      of these markers with different risk factors was assessed. Of the 22 
      ferroptosis-related genes, the expression of HSPA5, HSPB1, glutathione peroxidase 
      4, Fanconi anemia complementation group D2, CDGSH iron sulfur domain 1, 
      farnesyl-diphosphate farnesyltransferase 1, nuclear factor erythroid 2 like 2, 
      solute carrier (SLC)1A5, ribosomal protein L8, nuclear receptor coactivator 4, 
      transferrin receptor and SLC7A11 was significantly increased in LSCC compared 
      with adjacent tissues. However, only high expression of HSPA5 was able to predict 
      progression-free survival (PFS) and disease-free survival in LSCC. Although HSPA5 
      was also significantly elevated in patients with lung adenocarcinoma, HSPA5 
      expression did not predict the prognosis of patients with lung adenocarcinoma. Of 
      note, a higher expression of HSPA5 was related to higher responses to 
      chemotherapy but not to immunotherapy. In addition, HSPA5 expression was 
      positively correlated with 'ferroptosis', 'cellular responses to hypoxia', 'tumor 
      proliferation signature', 'G2M checkpoint', 'MYC targets' and 'TGFB'. IHC 
      analysis also demonstrated that a high expression of HSPA5 in patients with 
      metastatic LSCC in the study cohort was associated with shorter PFS and overall 
      survival. In conclusion, the present study demonstrated that the expression of 
      the ferroptosis-related gene HSPA5 may be a negative prognostic marker for LSCC.
CI  - Copyright: (c) 2024 Guo et al.
FAU - Guo, Di
AU  - Guo D
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
FAU - Feng, Yonghai
AU  - Feng Y
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
FAU - Liu, Peijie
AU  - Liu P
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
FAU - Yang, Shanshan
AU  - Yang S
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
FAU - Zhao, Wenfei
AU  - Zhao W
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
FAU - Li, Hongyun
AU  - Li H
AD  - Department of Respiratory and Critical Care Medicine, Fifth Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20240229
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10921261
OTO - NOTNLM
OT  - HSPA5
OT  - LSCC
OT  - NSCLC
OT  - biomarkers
OT  - ferroptosis
OT  - prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2024/03/11 06:42
MHDA- 2024/03/11 06:43
PMCR- 2024/02/29
CRDT- 2024/03/11 04:33
PHST- 2023/11/08 00:00 [received]
PHST- 2024/02/01 00:00 [accepted]
PHST- 2024/03/11 06:43 [medline]
PHST- 2024/03/11 06:42 [pubmed]
PHST- 2024/03/11 04:33 [entrez]
PHST- 2024/02/29 00:00 [pmc-release]
AID - OL-27-4-14320 [pii]
AID - 10.3892/ol.2024.14320 [doi]
PST - epublish
SO  - Oncol Lett. 2024 Feb 29;27(4):186. doi: 10.3892/ol.2024.14320. eCollection 2024 
      Apr.